$MTEM
Molecular Templates, Inc.

2019 Q3 Form 10-Q Financial Statement

#000156459019043009 Filed on November 12, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2018 Q4 2018 Q3
Revenue $3.618M $4.680M $6.752M
YoY Change -46.42% 470.73% 941.98%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.510M $3.920M $3.540M
YoY Change 27.4% 11.36% -11.5%
% of Gross Profit
Research & Development $15.25M $7.560M $8.290M
YoY Change 83.94% 62.23% 228.71%
% of Gross Profit
Depreciation & Amortization $500.0K $400.0K $400.0K
YoY Change 25.0% 344.44% 1233.33%
% of Gross Profit
Operating Expenses $41.88M $11.48M $8.290M
YoY Change 405.2% 40.34% 27.19%
Operating Profit -$38.26M
YoY Change
Interest Expense $396.0K $160.0K $279.0K
YoY Change 41.94% -54.29% 160.75%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$38.22M -$6.630M -$5.240M
YoY Change 629.37% -4.19% -52.23%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$38.22M -$6.630M -$5.240M
YoY Change 629.37% -4.19% -52.22%
Net Earnings / Revenue -1056.36% -141.67% -77.61%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.035M -$180.8K -$189.3K
COMMON SHARES
Basic Shares Outstanding 36.94M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3 2018 Q4 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $51.40M $97.96M $78.70M
YoY Change -34.69% 66.28% 15.4%
Cash & Equivalents $15.27M $87.72M $78.74M
Short-Term Investments $36.10M $10.23M
Other Short-Term Assets $300.0K $95.00K $6.900M
YoY Change -95.65% 400.0% 392.86%
Inventory
Prepaid Expenses $2.244M $2.535M
Receivables $0.00 $200.0K $31.20M
Other Receivables $5.600M $4.400M $0.00
Total Short-Term Assets $64.15M $104.9M $116.8M
YoY Change -45.08% 73.57% 67.86%
LONG-TERM ASSETS
Property, Plant & Equipment $13.88M $6.851M $7.200M
YoY Change 92.83% 250.97% 647.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change
Other Assets $4.735M $1.821M $1.300M
YoY Change 264.23% 29.89% 1200.0%
Total Long-Term Assets $29.02M $35.30M $35.20M
YoY Change -17.57% 17.74% 6.93%
TOTAL ASSETS
Total Short-Term Assets $64.15M $104.9M $116.8M
Total Long-Term Assets $29.02M $35.30M $35.20M
Total Assets $93.16M $140.2M $152.0M
YoY Change -38.71% 55.06% 48.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.414M $780.0K $1.600M
YoY Change -11.63% -69.01% -57.89%
Accrued Expenses $9.105M $5.357M $6.600M
YoY Change 37.95% 99.14% 340.0%
Deferred Revenue $11.96M $26.23M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $24.10M $32.51M $41.70M
YoY Change -42.21% 211.33% 268.8%
LONG-TERM LIABILITIES
Long-Term Debt $3.001M $3.254M $3.155M
YoY Change -4.88% 201.86% 81.95%
Other Long-Term Liabilities $1.238M $819.0K $844.0K
YoY Change 46.68% 30.41% -47.25%
Total Long-Term Liabilities $4.239M $4.073M $3.999M
YoY Change 6.0% 138.75% 130.62%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.10M $32.51M $41.70M
Total Long-Term Liabilities $4.239M $4.073M $3.999M
Total Liabilities $40.15M $39.25M $45.80M
YoY Change -12.34% 199.59% 212.88%
SHAREHOLDERS EQUITY
Retained Earnings -$148.2M -$94.70M
YoY Change 46.89%
Common Stock $201.2M $195.6M
YoY Change 37.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $53.02M $100.9M $106.2M
YoY Change
Total Liabilities & Shareholders Equity $93.16M $140.2M $152.0M
YoY Change -38.71% 55.06% 48.24%

Cashflow Statement

Concept 2019 Q3 2018 Q4 2018 Q3
OPERATING ACTIVITIES
Net Income -$38.22M -$6.630M -$5.240M
YoY Change 629.37% -4.19% -52.22%
Depreciation, Depletion And Amortization $500.0K $400.0K $400.0K
YoY Change 25.0% 344.44% 1233.33%
Cash From Operating Activities -$16.39M $19.39M -$9.720M
YoY Change 68.62% -345.13% 139.41%
INVESTING ACTIVITIES
Capital Expenditures -$5.210M -$300.0K -$1.230M
YoY Change 323.58% -58.9% 251.43%
Acquisitions
YoY Change
Other Investing Activities $19.59M -$10.22M $0.00
YoY Change -100.0%
Cash From Investing Activities $14.39M -$10.53M -$1.230M
YoY Change -1269.92% 1342.47% -111.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 480.0K 110.0K 48.05M
YoY Change -99.0% -117.46% -15.57%
NET CHANGE
Cash From Operating Activities -16.39M 19.39M -9.720M
Cash From Investing Activities 14.39M -10.53M -1.230M
Cash From Financing Activities 480.0K 110.0K 48.05M
Net Change In Cash -1.520M 8.970M 37.10M
YoY Change -104.1% -196.76% -41.65%
FREE CASH FLOW
Cash From Operating Activities -$16.39M $19.39M -$9.720M
Capital Expenditures -$5.210M -$300.0K -$1.230M
Free Cash Flow -$11.18M $19.69M -$8.490M
YoY Change 31.68% -374.23% 128.84%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
mtem Interest And Other Expense Net
InterestAndOtherExpenseNet
672000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27246667
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5244000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53520000
us-gaap Net Income Loss
NetIncomeLoss
-23653000
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10397000
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13884000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6851000
CY2019Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4735000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1821000
CY2019Q3 us-gaap Assets
Assets
93162000
CY2018Q4 us-gaap Assets
Assets
140158000
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1414000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
780000
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9105000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5357000
CY2019Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
11956000
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
26231000
CY2019Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1623000
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
141000
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
24098000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
32509000
CY2019Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1236000
CY2018Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2670000
CY2019Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3001000
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3254000
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10573000
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2019Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1238000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
819000
CY2019Q3 us-gaap Liabilities
Liabilities
40146000
CY2018Q4 us-gaap Liabilities
Liabilities
39252000
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
37000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
37000
CY2019Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
201203000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
195573000
CY2019Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
20000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-148244000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-94704000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
53016000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
100906000
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
93162000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
140158000
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36954510
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36736012
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36954510
CY2019Q3 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
0
CY2019Q3 mtem In Process Research And Development Held For Sale Current
InProcessResearchAndDevelopmentHeldForSaleCurrent
4500000
CY2019Q3 us-gaap Other Assets Current
OtherAssetsCurrent
300000
CY2018Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
240000
CY2018Q4 mtem In Process Research And Development Held For Sale Current
InProcessResearchAndDevelopmentHeldForSaleCurrent
26623000
CY2019Q3 us-gaap Assets Current
AssetsCurrent
64146000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23653000
CY2019Q3 us-gaap Long Term Debt
LongTermDebt
3000000
CY2018Q4 us-gaap Long Term Debt
LongTermDebt
3300000
us-gaap Operating Expenses
OperatingExpenses
70118000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
916000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-53540000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23653000
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.03
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.45
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.87
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36937912
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27680307
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36832966
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36736012
CY2019Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3618000
CY2018Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6752000
us-gaap Share Based Compensation
ShareBasedCompensation
4330000
us-gaap Share Based Compensation
ShareBasedCompensation
2762000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
347000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
219000
CY2018Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
3000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
916000
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
48000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
16073000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8601000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15249000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8290000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4509000
CY2019Q3 mtem Loss On Impairment Of In Process Research And Development
LossOnImpairmentOfInProcessResearchAndDevelopment
22123000
CY2018Q3 mtem Loss On Impairment Of In Process Research And Development
LossOnImpairmentOfInProcessResearchAndDevelopment
0
mtem Loss On Impairment Of In Process Research And Development
LossOnImpairmentOfInProcessResearchAndDevelopment
22123000
mtem Loss On Impairment Of In Process Research And Development
LossOnImpairmentOfInProcessResearchAndDevelopment
0
us-gaap Operating Income Loss
OperatingIncomeLoss
-24204000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1449000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
307000
mtem Interest And Other Expense Net
InterestAndOtherExpenseNet
947000
CY2019Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1000
CY2018Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
4000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
3000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
20000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38224000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
89260000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
62177000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
106192000
us-gaap Net Income Loss
NetIncomeLoss
-53540000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
628000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
569000
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
28000
us-gaap Interest Costs Capitalized Adjustment
InterestCostsCapitalizedAdjustment
0
us-gaap Interest Costs Capitalized Adjustment
InterestCostsCapitalizedAdjustment
125000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-115000
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
22139000
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
96000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1116000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-240000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
31163000
mtem Increase Decrease In Grants Revenue Receivable
IncreaseDecreaseInGrantsRevenueReceivable
1262000
mtem Increase Decrease In Grants Revenue Receivable
IncreaseDecreaseInGrantsRevenueReceivable
4100000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
145000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
156000
mtem Increase Decrease In Operating Lease Right Of Use Assets Non Current
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNonCurrent
-1077000
mtem Increase Decrease In Operating Lease Right Of Use Assets Non Current
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNonCurrent
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
524000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-906000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2661000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3733000
mtem Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-511000
mtem Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
0
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
215000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-15709000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
30635000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39272000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23859000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6329000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5421000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
73758000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
48583000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-31504000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5421000
mtem Payments Of Capital And Financing Lease Obligations
PaymentsOfCapitalAndFinancingLeaseObligations
-23000
mtem Payments Of Capital And Financing Lease Obligations
PaymentsOfCapitalAndFinancingLeaseObligations
36000
mtem Proceeds From Issuance Of Long Term Debt And Warrants Net
ProceedsFromIssuanceOfLongTermDebtAndWarrantsNet
0
mtem Proceeds From Issuance Of Long Term Debt And Warrants Net
ProceedsFromIssuanceOfLongTermDebtAndWarrantsNet
4537000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
3605000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1300000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
157000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48061000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1323000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
49114000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-69453000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
19834000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
87721000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
58910000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18268000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
78744000
us-gaap Interest Paid Net
InterestPaidNet
514000
us-gaap Interest Paid Net
InterestPaidNet
286000
mtem Fixed Asset Additions In Accounts Payable And Accrued Expenses
FixedAssetAdditionsInAccountsPayableAndAccruedExpenses
1197000
mtem Fixed Asset Additions In Accounts Payable And Accrued Expenses
FixedAssetAdditionsInAccountsPayableAndAccruedExpenses
192000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.42%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash and cash equivalents, investments, long term debt and accounts receivable.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.42%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s cash and cash equivalents are with two major financial institutions in the United States. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.42%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company performs an ongoing credit evaluation of its strategic partners&#8217; financial conditions and generally does not require collateral to secure accounts receivable from its strategic partners. The Company&#8217;s exposure to credit risk associated with non-payment will be affected principally by conditions or occurrences within Takeda Pharmaceutical Company Ltd. (&#8220;Takeda&#8221;). Takeda accounted for approximately 80% and 28% of total revenues for the three months ended September&#160;30, 2019 and 2018, respectively. Takeda accounted for approximately 90% and 35% of total revenues for the nine months ended September&#160;30, 2019 and 2018, respectively. There were no accounts receivable due from Takeda at September&#160;30, 2019. There were $0.2 million in accounts receivable due from Takeda at December&#160;31, 2018. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.42%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Cancer Prevention Research Institute of Texas (&#8220;CPRIT&#8221;) accounted for approximately 12% and 70% of total revenues for the three months ended September&#160;30, 2019 and 2018, respectively. CPRIT accounted for approximately 8% and 63% of total revenues for the nine months ended September&#160;30, 2019 and 2018, respectively. There were $5.6 million in accounts receivable due from CPRIT at September&#160;30, 2019. There were $4.3 million in accounts receivable due from CPRIT at December&#160;31, 2018. See also Note 3, Research and Development Agreements, regarding the collaboration and grant agreements. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.42%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug candidates developed by the Company may require approvals or clearances from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or international regulatory agencies prior to commercial sales. There can be no assurance that the Company&#8217;s drug candidates will receive any of the required approvals or clearances. If the Company were to be denied approval or clearance or any such approval or clearance were to be delayed, it would have a material adverse impact on the Company.</p>
CY2019Q3 mtem Research And Development Revenues From Collaboration Agreements
ResearchAndDevelopmentRevenuesFromCollaborationAgreements
3187000
CY2018Q3 mtem Research And Development Revenues From Collaboration Agreements
ResearchAndDevelopmentRevenuesFromCollaborationAgreements
2031000
mtem Research And Development Revenues From Collaboration Agreements
ResearchAndDevelopmentRevenuesFromCollaborationAgreements
14811000
mtem Research And Development Revenues From Collaboration Agreements
ResearchAndDevelopmentRevenuesFromCollaborationAgreements
3206000
CY2019Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
51305000
CY2018Q4 mtem In Process Research And Development
InProcessResearchAndDevelopment
26600000
CY2019Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
51400000
CY2019Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
36147000
CY2018Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
95668000
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
10234000
CY2019Q3 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
1300000
CY2019Q3 mtem Accrued General And Administrative Current
AccruedGeneralAndAdministrativeCurrent
619000
CY2018Q4 mtem Accrued General And Administrative Current
AccruedGeneralAndAdministrativeCurrent
297000
CY2019Q3 mtem Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
1696000
CY2018Q4 mtem Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
598000
CY2019Q3 mtem Accrued Non Clinical Research And Manufacturing Operations Current
AccruedNonClinicalResearchAndManufacturingOperationsCurrent
4796000
CY2018Q4 mtem Accrued Non Clinical Research And Manufacturing Operations Current
AccruedNonClinicalResearchAndManufacturingOperationsCurrent
2644000
CY2019Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1950000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1787000
CY2019Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
44000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
31000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4180000
CY2019Q1 us-gaap Assets
Assets
4180000
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
976000
CY2019Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3729000
CY2019Q1 us-gaap Liabilities
Liabilities
4705000
CY2019Q1 mtem Area Of Land Of Additional Facility Lease Agreement
AreaOfLandOfAdditionalFacilityLeaseAgreement
57000
CY2019Q3 us-gaap Variable Lease Cost
VariableLeaseCost
124000
CY2019Q1 mtem Lease Expiration Month And Year
LeaseExpirationMonthAndYear
2028-08
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7200000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
7200000
CY2019Q3 us-gaap Asset Retirement Obligation
AssetRetirementObligation
400000
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
597000
us-gaap Operating Lease Cost
OperatingLeaseCost
1595000
us-gaap Variable Lease Cost
VariableLeaseCost
356000
CY2019Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
721000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1951000
CY2019Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
2000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
6000
CY2019Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
3000
CY2019Q3 mtem Finance Lease Expense
FinanceLeaseExpense
3000
mtem Finance Lease Expense
FinanceLeaseExpense
9000
CY2019Q3 us-gaap Sublease Income
SubleaseIncome
27000
us-gaap Sublease Income
SubleaseIncome
110000
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
963000
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
11536000
CY2019Q3 mtem Finance Lease Right Of Use Asset Gross
FinanceLeaseRightOfUseAssetGross
77000
CY2019Q3 mtem Finance Lease Right Of Use Asset Accumulated Depreciation
FinanceLeaseRightOfUseAssetAccumulatedDepreciation
39000
CY2019Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
38000
CY2019Q3 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:PropertyPlantAndEquipmentNet
CY2019Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
25000
CY2019Q3 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2019Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
3000
CY2019Q3 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
CY2019Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
28000
CY2019Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y1M6D
CY2019Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0674
CY2019Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0702
CY2019Q3 mtem Lessee Operating Lease Liability Payments Remainder Of Fiscal Year Net Of Tenant Improvement Allowances
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYearNetOfTenantImprovementAllowances
0
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2517000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2589000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2650000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1961000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
7236000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
16953000
CY2019Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3877000
CY2019Q3 mtem Lessee Operating Lease Liability Total Lease Payments Net Of Interest
LesseeOperatingLeaseLiabilityTotalLeasePaymentsNetOfInterest
13076000
CY2019Q3 mtem Finance Lease Liability Payments Remainder Of Fiscal Year Net Of Tenant Improvement Allowances
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYearNetOfTenantImprovementAllowances
8000
CY2019Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
21000
CY2019Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
0
CY2019Q3 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
0
CY2019Q3 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
0
CY2019Q3 us-gaap Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
0
CY2019Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
29000
CY2019Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
1000
us-gaap Operating Lease Payments
OperatingLeasePayments
979000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
3000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
23000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
7296000
CY2019Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
406000
CY2019Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2517000
CY2019Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2589000
CY2019Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2650000
CY2019Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1961000
CY2019Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
7236000
CY2019Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
17359000
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4599243
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.09
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
941908
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1587602
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
218498
CY2019Q3 mtem Upfront Fees Unamortized Balance Included In Prepaid Asset
UpfrontFeesUnamortizedBalanceIncludedInPrepaidAsset
1000000
CY2019Q3 us-gaap Contractual Obligation
ContractualObligation
41000000
mtem Development Costs Sharing Percentage Exercised
DevelopmentCostsSharingPercentageExercised
0.50
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1527000
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1197000
CY2019Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
14300000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M10D
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4002999
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1756650
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.43
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.24
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.95
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
23.00
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.79
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y4M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1500000
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5800000
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3000000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1600000
us-gaap Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
0
CY2019Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
22100000
CY2019Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16537000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8184000
CY2019Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2653000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1333000
CY2019Q3 us-gaap Depreciation
Depreciation
500000
CY2018Q3 us-gaap Depreciation
Depreciation
400000
us-gaap Depreciation
Depreciation
1300000
us-gaap Depreciation
Depreciation
600000

Files In Submission

Name View Source Status
0001564590-19-043009-index-headers.html Edgar Link pending
0001564590-19-043009-index.html Edgar Link pending
0001564590-19-043009.txt Edgar Link pending
0001564590-19-043009-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mtem-10q_20190930.htm Edgar Link pending
mtem-20190930.xml Edgar Link completed
mtem-20190930.xsd Edgar Link pending
mtem-20190930_cal.xml Edgar Link unprocessable
mtem-20190930_def.xml Edgar Link unprocessable
mtem-20190930_lab.xml Edgar Link unprocessable
mtem-20190930_pre.xml Edgar Link unprocessable
mtem-ex101_564.htm Edgar Link pending
mtem-ex311_563.htm Edgar Link pending
mtem-ex312_562.htm Edgar Link pending
mtem-ex321_561.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending